Journal of internal medicine. Supplement最新文献_第3页

Treatment of B-cell chronic lymphocytic leukaemia: current status and future perspectives. b细胞慢性淋巴细胞白血病的治疗:现状和未来展望。

Journal of internal medicine. Supplement Pub Date : 1997-01-01

E Montserrat, F Bosch, C Rozman

{"title":"Treatment of B-cell chronic lymphocytic leukaemia: current status and future perspectives.","authors":"E Montserrat, F Bosch, C Rozman","doi":"","DOIUrl":"","url":null,"abstract":"In the last two decades, important advances have been made in the biology, natural history, and prognosis of B-cell chronic lymphocytic leukaemia (CLL). In addition, treatment possibilities for patients with CLL have changed as a result of the identification of prognostic factors for survival and the availability of new drugs and treatment strategies. Patients in the early clinical stages (Binet A, Rai 0) with stable disease have a probability of long survival and should not be treated unless the disease progresses. In contrast, most patients with poor prognostic features, such as an advanced clinical stage (Binet B, C; Rai III, IV), diffuse bone-marrow infiltration or rapidly increasing blood lymphocyte levels, have a median survival probability of < 5 years and require therapy. Purine analogues are highly effective. Among these, fludarabine has become the treatment of choice for patients failing standard therapies. The role of purine analogues either alone or in combination with other drugs as front-line therapy is being investigated. Certain situations (e.g. autoimmune cytopenias, hypersplenism) require special treatment approaches (e.g. corticosteroids, splenectomy). Transplants of progenitor haematopoietic cells are also increasingly performed and deserve further investigation in younger patients with poor prognostic features. As a result of these advances, symptoms palliation is no longer the only possible goal in CLL therapy; sustained remissions and even cures are likely to be obtained in the near future.","PeriodicalId":77556,"journal":{"name":"Journal of internal medicine. Supplement","volume":"740 ","pages":"63-7"},"PeriodicalIF":0.0,"publicationDate":"1997-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20281336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Empirical and subsequent use of antibacterial agents in the febrile neutropenic patient. 抗菌药物在发热性中性粒细胞减少症患者中的应用。

Journal of internal medicine. Supplement Pub Date : 1997-01-01

B E De Pauw, J M Raemaekers, T Schattenberg, J P Donnelly

{"title":"Empirical and subsequent use of antibacterial agents in the febrile neutropenic patient.","authors":"B E De Pauw, J M Raemaekers, T Schattenberg, J P Donnelly","doi":"","DOIUrl":"","url":null,"abstract":"Unlabelled: The objective of this analysis were an assessment of the feasibility of a more individually tailored approach of empirical antibiotic therapy in febrile neutropenia and an exploration of the reasons to modify the initial regimen.Design, setting and subjects: The main source was a database on febrile neutropenic cancer patients from an unblinded large trial conducted in 35 centres world-wide. This was supplemented by data from patients enrolled in a consecutive series of randomized trials at the Department of Haematology, University Hospital Nijmegen.Interventions: Diagnostic procedures were standardized, types of possible infections defined and the reasons for modifying an empirical regimen were recorded.Main outcome measures: Survival of the febrile neutropenic episode, development of microbiologically and clinically defined infection in relation to causative organisms, and results of modification.Results: Monotherapy was as effective as combination therapy with an overall mortality of < or = 7%, with 21% of neutropenic episodes accompanied by a clinically defined infection proving fatal compared with only 4% of episodes without a focus. At the end of treatment the empirical regimen had been added to in 60% of cases in the multicentre trial, in contrast to 39% in our own institution, in many cases simply because of continuing fever.Conclusion: The development of local guidelines for individually tailoring antibiotic therapy by complementing the empirical regimen is a feasible option for achieving an optimal anti-infective strategy for febrile neutropenic cancer patients.","PeriodicalId":77556,"journal":{"name":"Journal of internal medicine. Supplement","volume":"740 ","pages":"69-77"},"PeriodicalIF":0.0,"publicationDate":"1997-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20281337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antifungal treatment in patients with cancer. 癌症患者的抗真菌治疗。

Journal of internal medicine. Supplement Pub Date : 1997-01-01

C Viscoli, E Castagnola, M Machetti

引用次数: 0

Gene therapy of haematopoietic cells. 造血细胞的基因治疗。

Journal of internal medicine. Supplement Pub Date : 1997-01-01

S Karlsson

引用次数: 0

Transport proteins in drug resistance: biology and approaches to circumvention. 耐药转运蛋白:生物学和规避途径。

Journal of internal medicine. Supplement Pub Date : 1997-01-01

P R Twentyman

引用次数: 0

The influence of female sex steroids on glucose metabolism and insulin action. 雌性类固醇对糖代谢和胰岛素作用的影响。

Journal of internal medicine. Supplement Pub Date : 1996-01-01

I F Godsland

引用次数: 0

Moderately elevated blood pressure. A report from SBU, the Swedish Council on Technology Assessment in Health Care. 中度高血压。瑞典卫生保健技术评估委员会的一份报告。

Journal of internal medicine. Supplement Pub Date : 1995-01-01

引用次数: 0

Non-Insulin-Dependent Diabetes Mellitus and Atherosclerosis: a Lipoprotein Perspective. Symposium proceedings. London, United Kingdom, 3-4 December 1993. 非胰岛素依赖型糖尿病和动脉粥样硬化:脂蛋白的观点。研讨会论文集。1993年12月3日至4日，联合王国伦敦。

Journal of internal medicine. Supplement Pub Date : 1994-01-01

引用次数: 0

Dyslipoproteinaemia in manifest diabetes. 显性糖尿病患者的脂蛋白异常血症。

Journal of internal medicine. Supplement Pub Date : 1994-01-01

E Manzato, G Crepaldi

{"title":"Dyslipoproteinaemia in manifest diabetes.","authors":"E Manzato, G Crepaldi","doi":"","DOIUrl":"","url":null,"abstract":"The prevalence of hypercholesterolaemia is similar in non-insulin-dependent diabetic (NIDDM) patients and in non-diabetic subjects. The prevalence of hypertriglyceridaemia and of low high-density-lipoprotein (HDL) cholesterol is roughly double the norm in NIDDM, but the exact prevalence varies greatly from study to study. Obesity and a familial form of hypertriglyceridaemia (conditions that may alter plasma lipoprotein levels) are frequently observed in NIDDM patients. In carefully controlled NIDDM patients without concomitant primary hyperlipoproteinaemia, body weight may be more important than glycaemic control or the type of treatment plan adopted in determining lipoprotein levels. Hypertriglyceridaemia in NIDDM is a result of both increased very-low-density-lipoprotein (VLDL) synthesis and impaired VLDL catabolism. Whilst low-density-lipoprotein (LDL) levels are normal, the LDL synthesis and removal rates may be increased. Low high-density-lipoprotein (HDL) levels may be due to increased catabolism. In addition to quantitative changes in plasma lipids and lipoproteins. NIDDM patients demonstrate qualitative lipoprotein alterations. The size and density of LDL particles in NIDDM patients are greatly affected by triglyceride levels. Smaller, denser LDL particles have been observed in hypertriglyceridaemic subjects. Glycosylation of apolipoproteins may alter the metabolic properties of lipoproteins. Glycosylated and small, dense LDL have an increased susceptibility to oxidation.","PeriodicalId":77556,"journal":{"name":"Journal of internal medicine. Supplement","volume":"736 ","pages":"27-31"},"PeriodicalIF":0.0,"publicationDate":"1994-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18981411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Triglyceride-rich lipoproteins and atherosclerosis: pathophysiological considerations. 富甘油三酯脂蛋白和动脉粥样硬化:病理生理学考虑。

Journal of internal medicine. Supplement Pub Date : 1994-01-01

W A Bradley, S H Gianturco

引用次数: 0